ADC THERAPEUTICS SA (ADCT)
Health Care · Antibody-drug conjugates (ADCs) / targeted oncology therapeutics · NYSE
ADC Therapeutics develops antibody-drug conjugates (ADCs) targeting hematologic and solid tumors, with its lead product ZYNLONTA commercialized for lymphoma.
What ADC THERAPEUTICS SA does
ADC Therapeutics is a clinical-stage pharmaceutical company specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company commercializes ZYNLONTA (loncastuximab tesirine-lpyl), an ADC for relapsed/refractory diffuse large B-cell lymphoma, while advancing a pipeline of clinical-stage product candidates targeting both hematologic and solid tumors. The company generates revenue from product sales of ZYNLONTA and through license/royalty agreements, though it currently operates at a substantial net loss.
Themes: oncology, antibody-drug conjugates, targeted cancer therapy, hematology
Fundamentals
- Price$0.9966 as of 2026-08-21 close
- Market cap$127M as of 2026-08-21
- 1-year return-67.9% 2025-08-21 close $3.10 → 2026-08-21 close $0.9966
- P/En/a negative earnings
- Net margin-173.0% as of 2026-08-24
- Gross margin+90.7% as of 2026-08-24
- ROE-229.2% as of 2026-08-24
- Debt / equity9.01 as of 2026-08-24
- Revenue growth (YoY)+4.4% as of 2026-08-24
- Revenue CAGR (3y)-27.1% SEC XBRL
- Beta1.86 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How ADCT compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ADC THERAPEUTICS SA looks technically
ADC THERAPEUTICS SA (ADCT) is trading 68.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 60 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 79.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 68.4% below its 200-day average, the long-term trend line — a long-term downtrend | -68.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.14 | $1.14 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.16 | $3.16 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 0.9393. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a five-part sequence in leg 4. | possible three-wave downward correction, complete (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 60 trading days ago — a "death cross", a bearish long-term signal | 60 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) | 22.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30) | 38.5 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($0.9393 to $1.23) — its "stochastic" reading is 20 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 19.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 39 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $4.97 | $4.97 |
|---|---|---|
| From the 52-week high | it is 79.9% below its 52-week high (its highest price of the past year) | -80.0% |
| Above the 52-week low | it is 27.8% above its 52-week low (its lowest price of the past year) | +27.8% |
| Below the 52-week high | it is 79.9% below its highest point of the past year | 80.0% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $56.59 (set on 2020-07-02) | $56.59 |
| Given back of the 52-week move | over the past year its closes ranged ($0.9601 to $4.88), and it has recovered essentially none of its fall from last year’s high — 1% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.38 to $3.51. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.9% |
| From the all-time high | it is 98.2% below its all-time high | -98.2% |
| Nearest price level | it is trading 23.2% below a resistance level at $1.23 — a price it turned at twice since 2025-05-08, most recently on 2026-08-12. Since 2024-08-21 it has 0 such levels below the current price and 13 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +23.2% |
| All-time low | its lowest closing price on record is $0.3599 (set on 2023-11-13) | $0.3599 |
| Above the all-time low | it is 176.9% above its all-time low | +176.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 35th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0925 between its high and its low — about 9.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0925 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.96 and $1.21 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.96 – $1.09 – $1.21 |
| Typical daily range (% of price) | its price moves about 9.3% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 9.3% |
| Stretch from the 200-day average | it is trading 23.3 daily ranges below its 200-day average price (68.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 23.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.97× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 33.3% since the prior reading | -33.3% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.4% |
|---|---|---|
| Open gap | it gapped 4.6% below the previous close 3 sessions ago and has not traded back through the level it left behind at 1.1 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -4.5% |
| Gap filled | a 2.9% gap down opened on 2026-08-14 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 4 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 23.9 percentage points (the stock lost 21.5% while the market gained 2.3%) | -23.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 73.8 percentage points (the stock lost 70.7% while the market gained 3.1%) | -73.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 86.8 percentage points (the stock lost 75.7% while the market gained 11.1%) | -86.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 88.3 percentage points (the stock lost 67.9% while the market gained 20.5%) | -88.3% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: MACD momentum is positive, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 17% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 126.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -16.9% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 60% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.51 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -60.3% |
|---|
Price levels it has turned at before
ADCT last closed at $0.9966 on 2026-08-21. Since 2024-08-21 it has turned at 0 prices below its last close and 13 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.23 | Resistance | 23.2% above the last close | turned there twice · 2025-05-08 to 2026-08-12 |
| $1.50 | Resistance | 50.5% above the last close | turned there twice · 2025-03-04 to 2025-04-28 |
| $1.80 | Resistance | 80.6% above the last close | turned there twice · 2024-12-05 to 2024-12-13 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $0.9393.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a five-part sequence in leg 4, which fails on a close above $1.03.
This reading has stood for 2 trading days, since 2026-08-20.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · Analyst price target recently CUT · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.80 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$3.33 range $2.00 – $5.00; median $3.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["History of substantial net losses and expectation to continue incurring losses for the foreseeable future.","Significant indebtedness and restrictive covenants under existing loan agreements.","Financial obligations related to royalty purchase agreements that impact cash flow from ZYNLONTA."]
What changed in the latest 10-Q
AI-assisted comparison of ADCT's 10-Q filed 2026-05-04 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-04) adds specific financial results table for Q1 2026 vs Q1 2025 showing product revenues of $20.0M vs $17.4M, license revenues of $0.8M vs $5.6M, and net loss of $32.9M vs $38.6M
- Newer filing describes product revenue increase of $2.6M (15.1%) primarily attributable to higher sales volume and higher price
- Newer filing includes detailed breakdown of operating expenses for Q1 2026 vs Q1 2025 showing cost of product sales, R&D, selling and marketing, and G&A
- Newer filing states total other expense decreased from $9.973M to $7.723M
- Removed:
- Older filing (2025-11-10) describes company as 'commercial-stage global leader' whereas newer filing (2026-05-04) describes as 'commercial-stage global pioneer'
- Older filing mentions headquarters in Lausanne (Biopôle), Switzerland with operations in London and New Jersey; this geographic description is removed in newer filing
- Older filing discusses 'early stage prostate-specific membrane antigen targeting ADC (PSMA-targeting ADC)' as part of focused portfolio; removed in newer filing
- Older filing discusses description of driving innovation with 'specialized capabilities from clinical to manufacturing and commercialization'; removed in newer filing
- Older filing includes detail that ZYNLONTA received 'conditional approval' from NMPA and Health Canada; newer filing removes 'conditional' descriptor
- Older filing describes ZYNLONTA expansion 'as a single agent and in combination'; newer filing removes 'as a single agent and' language
- Older filing includes section on June 2025 restructuring, UK facility shutdown, 30% workforce reduction, and June/October 2025 private placement details; these are removed in newer filing
- Older filing includes extensive LOTIS-5 and LOTIS-7 clinical trial details with specific patient numbers, response rates, and safety data; these clinical trial details are removed in newer filing
- Reworded:
- Older filing: 'conditional approval from the European Commission' vs Newer filing: no mention of European Commission conditional status
- Older filing describes ZYNLONTA as 'our flagship product' whereas newer filing uses simpler descriptor
- Older filing states 'we are seeking to continue expanding' whereas newer filing states 'we are pursuing expansion'
- Notes:
- The newer filing appears to be a Q1 2026 10-Q (quarter ended March 31, 2026) while the older filing is a Q3 2025 10-Q (quarter ended September 30, 2025); the different reporting periods explain many of the content differences
- The removal of clinical trial details and restructuring information may reflect different scope of MD&A sections rather than substantive changes to disclosed information
Risk Factors
- Added:
- New line item in Balance Sheet (newer filing, March 31, 2026): Warrant obligations of $18,527 thousand
- New line item in Balance Sheet (newer filing, March 31, 2026): Senior secured term loans, current portion of $4,635 thousand
- New line item in Balance Sheet (newer filing, March 31, 2026): Inventory, long-term of $12,282 thousand
- Newer filing shows warrant obligations liability that did not exist in older filing's balance sheet
- Removed:
- Older filing (Sept 30, 2025) showed Property and equipment, net of $0 thousand; newer filing (March 31, 2026) does not show this line item
- Older filing (Sept 30, 2025) included 'Restructuring, impairment and other related costs' of $(377) thousand in operating expenses; newer filing (Q1 2026) does not show this expense category
- Older filing included 'Equity in net losses of joint venture' and 'Share of other comprehensive loss in joint venture' line items; newer filing does not include these
- Reworded:
- Older filing references 'this quarterly report on Form 10-Q' while newer filing states 'our Annual Report on Form 10-K' in the opening Risk Factors paragraph
- Balance sheet presentation changed: Older filing showed 'Senior secured term loans' as single line item; newer filing splits into 'Senior secured term loans, current portion' and 'Senior secured term loans, long-term'
- Older filing showed 'Operating lease right-of-use assets' separately; newer filing combined into asset presentation with different formatting
- Older filing identified commitment reference as 'Note 12'; newer filing identifies as 'Note 9'
- Notes:
- The two filings cover different periods (Q1 2026 vs Q3 2025), which explains many numerical and operational differences
- The older filing is a 10-Q for nine-month period ending September 30, 2025; the newer filing is a 10-Q for three-month period ending March 31, 2026
- Balance sheet dates are different (March 31, 2026 vs September 30, 2025 and December 31, 2024), limiting direct line-item comparisons
- The text provided appears truncated at the cash flows section in both filings
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 6 sells ($20M) — 1 selling insider
Most recent open-market transaction: 2026-04-02. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ADCT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
ADCT had 5,092,137 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ADCT had 3.99% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.11 days to cover at the same settlement.
- Reported short interest (shares) 5,092,137
- Short interest (% of shares outstanding) 3.99%
- Prior settlement (shares) 5,534,142
- Reported change -7.99%
- Days to cover (reported) 6.11
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Seagen (Pfizer) (PFE)
- ImmunoGen (AbbVie) (ABBV)
- Gilead Sciences (GILD)
- AstraZeneca (AZN)
- Daiichi Sankyo (DSNKY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ADCT vs…
ADC THERAPEUTICS SA is found in…
Frequently asked questions
What does ADC THERAPEUTICS SA (ADCT) do?
ADC Therapeutics is a clinical-stage pharmaceutical company specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company commercializes ZYNLONTA (loncastuximab tesirine-lpyl), an ADC for relapsed/refractory diffuse large B-cell lymphoma, while advancing a pipeline of clinical-stage product candidates targeting both hematologic and solid tumors.
What sector is ADC THERAPEUTICS SA (ADCT) in?
ADC THERAPEUTICS SA (ADCT) is classified in the Health Care sector. Its industry is Antibody-drug conjugates (ADCs) / targeted oncology therapeutics. It trades on NYSE.
Who are ADC THERAPEUTICS SA's (ADCT) competitors?
Notable peers of ADC THERAPEUTICS SA (ADCT) include Seagen (Pfizer), ImmunoGen (AbbVie), Gilead Sciences, AstraZeneca and Daiichi Sankyo. This peer set is informational only — not financial advice.
Is ADC THERAPEUTICS SA (ADCT) overbought or oversold right now?
ADC THERAPEUTICS SA (ADCT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 39, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ADCT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.